Small-molecule inhibitors generally act at or near the active site and block protease-catalyzed hydrolysis. A practical first step is therefore to select an inhibitor that matches the catalytic class of the protease expected in the sample.<\/p>\n
\u3000<\/p>\n
Selective Inhibition of the Target Protease<\/h4>\n
Even within the same protease class, inhibitor selection must take substrate specificity into account when a particular enzyme needs to be inhibited selectively. Among inhibitors of serine and cysteine proteases, for example, chymostatin preferentially inhibits chymotrypsin-like proteases, whereas leupeptin and antipain do not show comparable inhibition of α-chymotrypsin. Understanding the characteristic inhibition profile of each compound is therefore important.<\/p>\n
\u3000<\/p>\n
Building an Inhibitor Cocktail for the Experimental System<\/h4>\n
As described above, proteases differ in both catalytic mechanism and substrate specificity. To suppress the range of proteolytic activities that may coexist in a lysate, inhibitors with complementary mechanisms are commonly combined in a protease inhibitor cocktail.<\/p>\n
Commercial premixed cocktails are convenient, but their composition can be difficult to fine-tune for a particular experimental system. Peptide Institute supplies individual protease inhibitors, allowing researchers to build and adjust a cocktail according to their experimental design.<\/p>\n
\u3000<\/p>\n
Typical Situations in Which Cocktail Optimization Is Required<\/h4>\n\n- When the target protein is itself a protease or another enzyme whose activity may be affected<\/strong>
If the protein being recovered and purified is a protease, a premixed cocktail may also inhibit the desired target activity. Selecting only the necessary components makes it possible to preserve the activity of the target enzyme while suppressing degradation caused by unwanted proteases.<\/li>\n- When an inhibitor may interfere with downstream analysis or experiments<\/strong>
Certain inhibitors, including irreversible cysteine-protease inhibitors such as E-64, may affect subsequent mass spectrometry (MS) or cell-based assays. Excluding only the components that are incompatible with the downstream workflow can help minimize such interference.<\/li>\n<\/ul>\n\u3000
\n\u3000<\/p>\n
2. Detailed Profiles of Individual Protease Inhibitors<\/h3>\n\n\n\n\nInhibitor<\/th>\n Primary Target Proteases<\/th>\n Typical Working Concentration<\/th>\n Solvent<\/th>\n Inhibition Mode<\/th>\n Evidence \/ Notes<\/th>\n<\/tr>\n<\/thead>\n \n\nChymostatin<\/td>\n Serine (chymotrypsin-like) and selected cysteine proteases<\/td>\n 10–100 µM<\/td>\n DMSO<\/td>\n Reversible<\/td>\n Structure and properties reported[1]<\/sup>; slow-binding inhibition reported[2]<\/sup><\/td>\n<\/tr>\n\nLeupeptin<\/td>\n Serine and broad-range cysteine proteases<\/td>\n 10–100 µM<\/td>\n H2<\/sub>O<\/td>\nReversible<\/td>\n Inhibits plasmin, trypsin, and papain, but not α-chymotrypsin[3]<\/sup><\/td>\n<\/tr>\n\nAntipain<\/td>\n Serine and cysteine proteases (complementary coverage)<\/td>\n 1–10 µM<\/td>\n H2<\/sub>O (1 mM)<\/td>\nReversible<\/td>\n Reported as a novel protease inhibitor[4]<\/sup><\/td>\n<\/tr>\n\nE-64<\/td>\n Cysteine proteases (primary choice)<\/td>\n 10 µM<\/td>\n H2<\/sub>O<\/td>\nIrreversible<\/td>\n Properties reported for the novel inhibitor[5]<\/sup>; inhibition mechanism discussed[6]<\/sup><\/td>\n<\/tr>\n\nPepstatin A<\/td>\n Aspartic proteases<\/td>\n 1 µM<\/td>\n DMSO or EtOH:AcOH 9:1 (1 mM)<\/td>\n Reversible<\/td>\n Reported as a novel pepsin inhibitor[7]<\/sup>; inhibition mechanism reported[8]<\/sup><\/td>\n<\/tr>\n\nAprotinin<\/td>\n Serine proteases<\/td>\n 2–10 µg\/mL<\/td>\n H2<\/sub>O<\/td>\nReversible<\/td>\n Reviewed as a serine-protease inhibitor[9]<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\u3000<\/p>\n
2.1 Chymostatin<\/h4>\n
Target class:<\/strong> Serine and cysteine proteases, with preferential activity against chymotrypsin-like proteases
Inhibition mechanism:<\/strong> Reversible \/ peptide-aldehyde inhibition \/ slow-binding inhibition<\/p>\nChymostatin is a peptidic inhibitor that was identified and structurally characterized as a chymotrypsin inhibitor. Kinetic analysis has demonstrated potent slow-binding inhibition of chymotrypsin and cathepsin G[1,2]<\/sup>.<\/p>\n<\/p>\n
Structure and mode of action:<\/span> The C-terminal aldehyde group forms a reversible hemiacetal intermediate with the active-site serine residue of the target enzyme, or a hemithioacetal with an active-site cysteine residue, thereby inhibiting catalysis. Formation of the final high-affinity complex is time dependent, giving rise to slow-binding behavior.<\/p>\n\u3000<\/p>\n
2.2 Leupeptin<\/h4>\n
Target class:<\/strong> Serine proteases and a broad range of cysteine proteases
Inhibition mechanism:<\/strong> Reversible \/ peptide-aldehyde inhibition<\/p>\nLeupeptin strongly inhibits plasmin, trypsin, and papain but does not inhibit α-chymotrypsin, demonstrating a distinct substrate-specificity profile[3]<\/sup>.<\/p>\nStructure and mode of action:<\/span> Inhibition is mediated by the C-terminal aldehyde group. The arginine residue at the P1 position contributes to selectivity for trypsin-like proteases.<\/p>\n\n ![\"Chemical](\"\/img\/chem\/4041.gif\")
Chemical structure of leupeptin (Code 4041)<\/figcaption><\/figure>\n\u3000<\/p>\n
2.3 Antipain<\/h4>\n
Target class:<\/strong> Serine proteases and selected cysteine proteases (for complementary coverage)
Inhibition mechanism:<\/strong> Reversible \/ peptide-aldehyde inhibition<\/p>\nAntipain is an actinomycete-derived protease inhibitor that has long been used as a component of custom inhibitor cocktails. Trypsin is among its principal targets[4]<\/sup>.<\/p>\nStructure and mode of action:<\/span> Inhibition is mediated by the C-terminal aldehyde group.<\/p>\n\n ![\"Chemical](\"\/img\/chem\/4062.gif\")
Chemical structure of antipain (Code 4062)<\/figcaption><\/figure>\n\u3000<\/p>\n
2.4 E-64<\/h4>\n
Target class:<\/strong> Cysteine proteases (selective)
Inhibition mechanism:<\/strong> Irreversible \/ S-alkylation of the active-site cysteine \/ equimolar binding<\/p>\nE-64 was isolated as a novel thiol-protease inhibitor and is a potent inhibitor that binds irreversibly to papain, cathepsin B, and related enzymes at an equimolar ratio. Structure–activity studies of enzyme–inhibitor complexes have clarified its detailed mechanism of action. Derivatives with improved cell permeability, including E-64-d, have also been developed[5,6]<\/sup>.<\/p>\nStructure and mode of action:<\/span> The epoxysuccinyl moiety (epoxide ring) undergoes a selective nucleophilic reaction with the active-site thiol group of cysteine proteases. This irreversibly S-alkylates the catalytic cysteine and inhibits enzymatic activity.<\/p>\n\n ![\"Chemical](\"\/img\/chem\/4096.gif\")
Chemical structure of E-64 (Code 4096)<\/figcaption><\/figure>\n\u3000<\/p>\n
2.5 Pepstatin A<\/h4>\n
Target class:<\/strong> Aspartic proteases
Inhibition mechanism:<\/strong> Reversible \/ transition-state mimicry by the statine moiety<\/p>\nPepstatin A was discovered as an actinomycete-derived pepsin inhibitor and is widely used as a representative inhibitor of aspartic proteases. Pepsin is among the major targets for which inhibitory activity has been reported[7,8]<\/sup>.<\/p>\nStructure and mode of action:<\/span> Pepstatin A contains statine, an unusual non-proteinogenic amino-acid residue. This moiety mimics the transition state of protease-catalyzed hydrolysis. By binding noncovalently within the active-site pocket of an aspartic protease as a transition-state analogue, pepstatin A inhibits catalysis.<\/p>\n\n ![\"Chemical](\"\/img\/chem\/4397.gif\")
Chemical structure of pepstatin A (Code 4397)<\/figcaption><\/figure>\n\u3000<\/p>\n
2.6 Aprotinin<\/h4>\n
If the protein being recovered and purified is a protease, a premixed cocktail may also inhibit the desired target activity. Selecting only the necessary components makes it possible to preserve the activity of the target enzyme while suppressing degradation caused by unwanted proteases.<\/li>\n
Certain inhibitors, including irreversible cysteine-protease inhibitors such as E-64, may affect subsequent mass spectrometry (MS) or cell-based assays. Excluding only the components that are incompatible with the downstream workflow can help minimize such interference.<\/li>\n<\/ul>\n
\u3000
\n\u3000<\/p>\n
2. Detailed Profiles of Individual Protease Inhibitors<\/h3>\n\n\n\n\nInhibitor<\/th>\n Primary Target Proteases<\/th>\n Typical Working Concentration<\/th>\n Solvent<\/th>\n Inhibition Mode<\/th>\n Evidence \/ Notes<\/th>\n<\/tr>\n<\/thead>\n \n\nChymostatin<\/td>\n Serine (chymotrypsin-like) and selected cysteine proteases<\/td>\n 10–100 µM<\/td>\n DMSO<\/td>\n Reversible<\/td>\n Structure and properties reported[1]<\/sup>; slow-binding inhibition reported[2]<\/sup><\/td>\n<\/tr>\n\nLeupeptin<\/td>\n Serine and broad-range cysteine proteases<\/td>\n 10–100 µM<\/td>\n H2<\/sub>O<\/td>\nReversible<\/td>\n Inhibits plasmin, trypsin, and papain, but not α-chymotrypsin[3]<\/sup><\/td>\n<\/tr>\n\nAntipain<\/td>\n Serine and cysteine proteases (complementary coverage)<\/td>\n 1–10 µM<\/td>\n H2<\/sub>O (1 mM)<\/td>\nReversible<\/td>\n Reported as a novel protease inhibitor[4]<\/sup><\/td>\n<\/tr>\n\nE-64<\/td>\n Cysteine proteases (primary choice)<\/td>\n 10 µM<\/td>\n H2<\/sub>O<\/td>\nIrreversible<\/td>\n Properties reported for the novel inhibitor[5]<\/sup>; inhibition mechanism discussed[6]<\/sup><\/td>\n<\/tr>\n\nPepstatin A<\/td>\n Aspartic proteases<\/td>\n 1 µM<\/td>\n DMSO or EtOH:AcOH 9:1 (1 mM)<\/td>\n Reversible<\/td>\n Reported as a novel pepsin inhibitor[7]<\/sup>; inhibition mechanism reported[8]<\/sup><\/td>\n<\/tr>\n\nAprotinin<\/td>\n Serine proteases<\/td>\n 2–10 µg\/mL<\/td>\n H2<\/sub>O<\/td>\nReversible<\/td>\n Reviewed as a serine-protease inhibitor[9]<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\u3000<\/p>\n
2.1 Chymostatin<\/h4>\n
Target class:<\/strong> Serine and cysteine proteases, with preferential activity against chymotrypsin-like proteases
Inhibition mechanism:<\/strong> Reversible \/ peptide-aldehyde inhibition \/ slow-binding inhibition<\/p>\nChymostatin is a peptidic inhibitor that was identified and structurally characterized as a chymotrypsin inhibitor. Kinetic analysis has demonstrated potent slow-binding inhibition of chymotrypsin and cathepsin G[1,2]<\/sup>.<\/p>\n<\/p>\n
Structure and mode of action:<\/span> The C-terminal aldehyde group forms a reversible hemiacetal intermediate with the active-site serine residue of the target enzyme, or a hemithioacetal with an active-site cysteine residue, thereby inhibiting catalysis. Formation of the final high-affinity complex is time dependent, giving rise to slow-binding behavior.<\/p>\n\u3000<\/p>\n
2.2 Leupeptin<\/h4>\n
Target class:<\/strong> Serine proteases and a broad range of cysteine proteases
Inhibition mechanism:<\/strong> Reversible \/ peptide-aldehyde inhibition<\/p>\nLeupeptin strongly inhibits plasmin, trypsin, and papain but does not inhibit α-chymotrypsin, demonstrating a distinct substrate-specificity profile[3]<\/sup>.<\/p>\nStructure and mode of action:<\/span> Inhibition is mediated by the C-terminal aldehyde group. The arginine residue at the P1 position contributes to selectivity for trypsin-like proteases.<\/p>\n\n Chemical structure of leupeptin (Code 4041)<\/figcaption><\/figure>\n\u3000<\/p>\n
2.3 Antipain<\/h4>\n
Target class:<\/strong> Serine proteases and selected cysteine proteases (for complementary coverage)
Inhibition mechanism:<\/strong> Reversible \/ peptide-aldehyde inhibition<\/p>\nAntipain is an actinomycete-derived protease inhibitor that has long been used as a component of custom inhibitor cocktails. Trypsin is among its principal targets[4]<\/sup>.<\/p>\nStructure and mode of action:<\/span> Inhibition is mediated by the C-terminal aldehyde group.<\/p>\n\n Chemical structure of antipain (Code 4062)<\/figcaption><\/figure>\n\u3000<\/p>\n
2.4 E-64<\/h4>\n
Target class:<\/strong> Cysteine proteases (selective)
Inhibition mechanism:<\/strong> Irreversible \/ S-alkylation of the active-site cysteine \/ equimolar binding<\/p>\nE-64 was isolated as a novel thiol-protease inhibitor and is a potent inhibitor that binds irreversibly to papain, cathepsin B, and related enzymes at an equimolar ratio. Structure–activity studies of enzyme–inhibitor complexes have clarified its detailed mechanism of action. Derivatives with improved cell permeability, including E-64-d, have also been developed[5,6]<\/sup>.<\/p>\nStructure and mode of action:<\/span> The epoxysuccinyl moiety (epoxide ring) undergoes a selective nucleophilic reaction with the active-site thiol group of cysteine proteases. This irreversibly S-alkylates the catalytic cysteine and inhibits enzymatic activity.<\/p>\n\n Chemical structure of E-64 (Code 4096)<\/figcaption><\/figure>\n\u3000<\/p>\n
2.5 Pepstatin A<\/h4>\n
Target class:<\/strong> Aspartic proteases
Inhibition mechanism:<\/strong> Reversible \/ transition-state mimicry by the statine moiety<\/p>\nPepstatin A was discovered as an actinomycete-derived pepsin inhibitor and is widely used as a representative inhibitor of aspartic proteases. Pepsin is among the major targets for which inhibitory activity has been reported[7,8]<\/sup>.<\/p>\nStructure and mode of action:<\/span> Pepstatin A contains statine, an unusual non-proteinogenic amino-acid residue. This moiety mimics the transition state of protease-catalyzed hydrolysis. By binding noncovalently within the active-site pocket of an aspartic protease as a transition-state analogue, pepstatin A inhibits catalysis.<\/p>\n\n Chemical structure of pepstatin A (Code 4397)<\/figcaption><\/figure>\n\u3000<\/p>\n
2.6 Aprotinin<\/h4>\n
| Inhibitor<\/th>\n | Primary Target Proteases<\/th>\n | Typical Working Concentration<\/th>\n | Solvent<\/th>\n | Inhibition Mode<\/th>\n | Evidence \/ Notes<\/th>\n<\/tr>\n<\/thead>\n | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chymostatin<\/td>\n | Serine (chymotrypsin-like) and selected cysteine proteases<\/td>\n | 10–100 µM<\/td>\n | DMSO<\/td>\n | Reversible<\/td>\n | Structure and properties reported[1]<\/sup>; slow-binding inhibition reported[2]<\/sup><\/td>\n<\/tr>\n| Leupeptin<\/td>\n | Serine and broad-range cysteine proteases<\/td>\n | 10–100 µM<\/td>\n | H2<\/sub>O<\/td>\n | Reversible<\/td>\n | Inhibits plasmin, trypsin, and papain, but not α-chymotrypsin[3]<\/sup><\/td>\n<\/tr>\n | Antipain<\/td>\n | Serine and cysteine proteases (complementary coverage)<\/td>\n | 1–10 µM<\/td>\n | H2<\/sub>O (1 mM)<\/td>\n | Reversible<\/td>\n | Reported as a novel protease inhibitor[4]<\/sup><\/td>\n<\/tr>\n | E-64<\/td>\n | Cysteine proteases (primary choice)<\/td>\n | 10 µM<\/td>\n | H2<\/sub>O<\/td>\n | Irreversible<\/td>\n | Properties reported for the novel inhibitor[5]<\/sup>; inhibition mechanism discussed[6]<\/sup><\/td>\n<\/tr>\n | Pepstatin A<\/td>\n | Aspartic proteases<\/td>\n | 1 µM<\/td>\n | DMSO or EtOH:AcOH 9:1 (1 mM)<\/td>\n | Reversible<\/td>\n | Reported as a novel pepsin inhibitor[7]<\/sup>; inhibition mechanism reported[8]<\/sup><\/td>\n<\/tr>\n | Aprotinin<\/td>\n | Serine proteases<\/td>\n | 2–10 µg\/mL<\/td>\n | H2<\/sub>O<\/td>\n | Reversible<\/td>\n | Reviewed as a serine-protease inhibitor[9]<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n | \u3000<\/p>\n 2.1 Chymostatin<\/h4>\nTarget class:<\/strong> Serine and cysteine proteases, with preferential activity against chymotrypsin-like proteases Chymostatin is a peptidic inhibitor that was identified and structurally characterized as a chymotrypsin inhibitor. Kinetic analysis has demonstrated potent slow-binding inhibition of chymotrypsin and cathepsin G[1,2]<\/sup>.<\/p>\n <\/p>\n Structure and mode of action:<\/span> The C-terminal aldehyde group forms a reversible hemiacetal intermediate with the active-site serine residue of the target enzyme, or a hemithioacetal with an active-site cysteine residue, thereby inhibiting catalysis. Formation of the final high-affinity complex is time dependent, giving rise to slow-binding behavior.<\/p>\n \u3000<\/p>\n Target class:<\/strong> Serine proteases and a broad range of cysteine proteases Leupeptin strongly inhibits plasmin, trypsin, and papain but does not inhibit α-chymotrypsin, demonstrating a distinct substrate-specificity profile[3]<\/sup>.<\/p>\n Structure and mode of action:<\/span> Inhibition is mediated by the C-terminal aldehyde group. The arginine residue at the P1 position contributes to selectivity for trypsin-like proteases.<\/p>\n \u3000<\/p>\n Target class:<\/strong> Serine proteases and selected cysteine proteases (for complementary coverage) Antipain is an actinomycete-derived protease inhibitor that has long been used as a component of custom inhibitor cocktails. Trypsin is among its principal targets[4]<\/sup>.<\/p>\n Structure and mode of action:<\/span> Inhibition is mediated by the C-terminal aldehyde group.<\/p>\n \u3000<\/p>\n Target class:<\/strong> Cysteine proteases (selective) E-64 was isolated as a novel thiol-protease inhibitor and is a potent inhibitor that binds irreversibly to papain, cathepsin B, and related enzymes at an equimolar ratio. Structure–activity studies of enzyme–inhibitor complexes have clarified its detailed mechanism of action. Derivatives with improved cell permeability, including E-64-d, have also been developed[5,6]<\/sup>.<\/p>\n Structure and mode of action:<\/span> The epoxysuccinyl moiety (epoxide ring) undergoes a selective nucleophilic reaction with the active-site thiol group of cysteine proteases. This irreversibly S-alkylates the catalytic cysteine and inhibits enzymatic activity.<\/p>\n \u3000<\/p>\n Target class:<\/strong> Aspartic proteases Pepstatin A was discovered as an actinomycete-derived pepsin inhibitor and is widely used as a representative inhibitor of aspartic proteases. Pepsin is among the major targets for which inhibitory activity has been reported[7,8]<\/sup>.<\/p>\n Structure and mode of action:<\/span> Pepstatin A contains statine, an unusual non-proteinogenic amino-acid residue. This moiety mimics the transition state of protease-catalyzed hydrolysis. By binding noncovalently within the active-site pocket of an aspartic protease as a transition-state analogue, pepstatin A inhibits catalysis.<\/p>\n \u3000<\/p>\n |